Schedules of Controlled Substances: Placement of Centanafadine in Schedule III
Built by the Tribune's code from the Federal Register. No AI wrote this page. Published in the Federal Register Oct. 30, 2026. Document 2026-22208. Updated Nov. 5, 2026.
- What it does
On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged 6 years and older, weighing at least 20 kg. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place centanafadine, chemically known as (1R,5S)-1- (naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in schedule III of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing centanafadine, including its salts, isomers (whether optical, positional, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible in schedule III of the CSA.
The Drug Enforcement Administration's summary, as published in the Federal Register.
- What changed in the regulation
1 part of Title 21 of the Code of Federal Regulations:
Wording on eCFR: the day before it took effect and from the day it took effect (first part listed).
- Compared with
The Drug Enforcement Administration has published 25 final rules in 2026 so far, compared with 17 in all of 2025.
Counted by the Tribune from Federal Register records since Jan. 1, 2025.
- What happens next and when
This rule is effective October 30, 2026. Comments must be submitted electronically or postmarked on or before November 30, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
The agency's dates, word for word.
The record as published
| Document number | 2026-22208 |
|---|---|
| Action | Interim final rule; request for comments. |
| Agencies | Justice Department; Drug Enforcement Administration |
| Published | Oct. 30, 2026 |
| Effective date | Oct. 30, 2026 |
| Comments close | Nov. 30, 2026 |
| Docket | DEA-2026-1783 |
Source: the Federal Register (public domain). The document in the Federal Register